Most Popular Stories
- Healthcare jobs will grow the fastest of all industries
- Interview: Behind WellPoint's $1B primary care initiative
- Hospitals criticized for patient data-mining
- Smartphone-powered monitoring to rise to 3 million users by 2016
- Young docs fuel palliative medicine, reveal generational differences
- Health attorney: Google's new privacy policy does not violate HIPAA
Featured Jobs
-
Epic Ambulatory Beacon Consultant
Meditology Services - NC -
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA
Events
- Wharton Health Care Business Conference
Feb 16-17 — Philadelphia, PA - Medical Devices Summit 2012
March 6-7 2012 — The Boston Park Plaza Hotel & Towers, Boston, MA - CIO Healthcare Summit
March 11-14 — Scottsdale, AZ - AHIP's Institute 2012
June 20-22 — Salt Lake City, UT
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
SPOTLIGHT: Are costly cancer drugs worth the price?
March 19, 2007 — 7:01pm ET
Tools
With price tags that can hit a mind-boggling $100,000 for an annual supply, critics are increasingly questioning whether certain cancer drugs are worth the price, particularly given that they may only extent a patient's life for a few months. policymakers and clinicians are asking whether society should invest such a large sum on patients who are about to die either way. Article
SHARE WITH:
Related Stories
- Case study: Beth Israel Deaconess uses 'tag' game to boost hand washing
- CMS officials say they want RAC program to be fair
- SPOTLIGHT: Officials consider reasons for steep mammogram drop
- Kaiser suspends perinatologist over mistakes
- Trend: States try to counter pharma drug marketing
- "Behind the counter" non prescription meds considered
- ALSO NOTED: CalPERS cuts $225M deal with BC of California; D.C. retail clinic operator plans area expansion; and much more...
- Hospitals let families, patients activate rapid response
- Wash. state program increases pain med use
- ALSO NOTED: Senators approve CHIP expansion; Bill would give chronically-ill better insurance access; and much more...
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
